Drug Trial Radar · NCT03642288
The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction
Last checked: Nov 19, 2026Latest source record: Aug 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
112
Actual
Start
Apr 1, 2014
Primary completion
Jun 30, 2018
Study completion Dec 31, 2018
Sponsor
- Lead sponsor
- Jinling Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic radiation enteropathy (CRE) is a major issue for long-term cancer survivors. The aim of this study was to clarify the diagnostic and therapeutic effect of the Gastrografin (GG) challenge for patients with CRE induced small bowel obstruction SBO.
Conditions
- CRE-induced SBO
Interventions
GastrografinDrug
Patients with CRE-induced SBO or ASBO both received GG challenge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of successful conservative treatmentTime frame: 5 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.